Natalya M. Bychkova
Natalya M. Bychkova has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Guzal R. Abuzarova
P. A. Hertsen Moscow Oncology Research Institute – a branch of the National Medical Research Centre for Radiology of the Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia
5 shared publications - Regina R. Sarmanayeva
P. A. Hertsen Moscow Oncology Research Institute – a branch of the National Medical Research Centre for Radiology of the Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia
5 shared publications - Andrei Dmitrievich Kaprin
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia
3 shared publications - Evgeny V. Khmelevskiy
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre
3 shared publications - S. V. Kuznetcov
P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia
3 shared publications - Anna Viktorovna Yadrina
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in The EANM Journal
- Vol. 5
Imaging more, changing nothing: Are there predictors of unchanged management after [18F]PSMA-1007 PET/CT in primary staging of high-risk prostate cancer?
- 23 October 2026
- Published by Elsevier in The EANM Journal
- Vol. 5
Open AccessImaging more, changing nothing: Are there predictors of unchanged management after [18F]PSMA-1007 PET/CT in primary staging of high-risk prostate cancer?
- Open Access
- 18 December 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (4) , 420-425
A clinical case of treatment of recurrent inoperable locally advanced breast cancer using conformal radiotherapy. Case report
Despite advances in the early diagnosis of breast cancer (BC), the identification of locally advanced forms continues to be relevant. This is a complex category of patients whose treatment includes the complex use of various methods with significant medical and economic costs, long-term treatment and rehabilitation. A particular difficulty is the treatment in cases of progression of locally advanced forms. Patients with locally advanced BC require a multidisciplinary approach. In the absence of an effect after neoadjuvant drug treatment and the impossibility of performing surgical intervention, patients are treated with induction radiation therapy. The article describes the features of induction radiation therapy in the treatment of progression of primary inoperable BC in a specific clinical example. In case of recurrence of triple negative type of BC, the patient underwent various drug treatment regimens with the inclusion of immunotherapy. Due to the lack of effect from 3 lines of systemic drug treatment, it was decided to conduct radiation therapy. In connection with the identified carrier of a mutation in the BRCA1 gene, targeted therapy with PARP inhibitors was prescribed. Two months after radiation therapy and 1 month after the start of targeted therapy, the patient showed complete resorption of the tumor conglomerate on the anterior chest wall. The use of conformal radiation therapy in case of recurrence of the disease and the absence of the effect of systemic treatment made it possible to completely resorb an exophytic tumor with ulceration and achieve remission within the next 6 months.
- 18 December 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (4) , 420-425
Open AccessA clinical case of treatment of recurrent inoperable locally advanced breast cancer using conformal radiotherapy. Case report
Despite advances in the early diagnosis of breast cancer (BC), the identification of locally advanced forms continues to be relevant. This is a complex category of patients whose treatment includes the complex use of various methods with significant medical and economic costs, long-term treatment and rehabilitation. A particular difficulty is the treatment in cases of progression of locally advanced forms. Patients with locally advanced BC require a multidisciplinary approach. In the absence of an effect after neoadjuvant drug treatment and the impossibility of performing surgical intervention, patients are treated with induction radiation therapy. The article describes the features of induction radiation therapy in the treatment of progression of primary inoperable BC in a specific clinical example. In case of recurrence of triple negative type of BC, the patient underwent various drug treatment regimens with the inclusion of immunotherapy. Due to the lack of effect from 3 lines of systemic drug treatment, it was decided to conduct radiation therapy. In connection with the identified carrier of a mutation in the BRCA1 gene, targeted therapy with PARP inhibitors was prescribed. Two months after radiation therapy and 1 month after the start of targeted therapy, the patient showed complete resorption of the tumor conglomerate on the anterior chest wall. The use of conformal radiation therapy in case of recurrence of the disease and the absence of the effect of systemic treatment made it possible to completely resorb an exophytic tumor with ulceration and achieve remission within the next 6 months.
- Open Access
- 19 June 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 147-156
Projection into the future: combination of orphenadrine and diclofenac in patients with bone metastases
Introduction. Radiation therapy is an effective method of treating pain in patients with bone metastases, but during radiotherapy there is often an increase in pain. The presence of a new drug containing a combination of orphenadrine and diclofenac in oncologists expands the possibilities of analgesia.Aim. To evaluate the efficacy and safety of the use of a fixed combination of diclofenac and orphenadrine in patients with pain due to metastatic bone damage during radiotherapy.Materials and methods. The patients were randomized into two groups: the first group (n = 30) received the drug Neodolpasse intravenously once a day for two days; the second - 2 times a day (n = 30) - 2 days. Efficacy was evaluated based on the following measurements: intensity of pain by NRS immediately after administration of the drug, after 30 minutes, after 1, 2, 4 and 24 hours, the dynamics of daily doses of analgesics.Results and discussion. In group 1, a meaningful decrease in pain intensity (p < 0.05) from 48.7 ± 10.6 mm to 26.8 ± 10.7 mm was achieved 30 minutes after the completion of infusion. The pain intensity measured by the Numeric Rating Scale (NRS) reached its minimum value 2 hours after the completion of infusion (22.5 ± 12.0 mm). In group 2, the pain intensity decreased 30 minutes after the completion of infusion, a meaningful decrease (p < 0.05) in pain intensity was achieved from 56.5 ± 9.8 mm to 34.0 ± 10.5 mm, and up to 29.8 ± 10.2 mm after the second dose. The pain intensity decreased by 45.9% in group 1 and by 47.9% in group 2 towards the end of the Neodolpasse therapy cycle. During the study, two mild to moderate adverse events (nausea, drop in blood pressure) that did not require any significant drug therapy were observed.Conclusion. The results of the study confirm that the use of the drug according to the proposed method is a safe and effective way of treating pain syndrome during radiotherapy in patients with metastatic bone damage.
- 19 June 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 147-156
Open AccessProjection into the future: combination of orphenadrine and diclofenac in patients with bone metastases
Introduction. Radiation therapy is an effective method of treating pain in patients with bone metastases, but during radiotherapy there is often an increase in pain. The presence of a new drug containing a combination of orphenadrine and diclofenac in oncologists expands the possibilities of analgesia.Aim. To evaluate the efficacy and safety of the use of a fixed combination of diclofenac and orphenadrine in patients with pain due to metastatic bone damage during radiotherapy.Materials and methods. The patients were randomized into two groups: the first group (n = 30) received the drug Neodolpasse intravenously once a day for two days; the second - 2 times a day (n = 30) - 2 days. Efficacy was evaluated based on the following measurements: intensity of pain by NRS immediately after administration of the drug, after 30 minutes, after 1, 2, 4 and 24 hours, the dynamics of daily doses of analgesics.Results and discussion. In group 1, a meaningful decrease in pain intensity (p < 0.05) from 48.7 ± 10.6 mm to 26.8 ± 10.7 mm was achieved 30 minutes after the completion of infusion. The pain intensity measured by the Numeric Rating Scale (NRS) reached its minimum value 2 hours after the completion of infusion (22.5 ± 12.0 mm). In group 2, the pain intensity decreased 30 minutes after the completion of infusion, a meaningful decrease (p < 0.05) in pain intensity was achieved from 56.5 ± 9.8 mm to 34.0 ± 10.5 mm, and up to 29.8 ± 10.2 mm after the second dose. The pain intensity decreased by 45.9% in group 1 and by 47.9% in group 2 towards the end of the Neodolpasse therapy cycle. During the study, two mild to moderate adverse events (nausea, drop in blood pressure) that did not require any significant drug therapy were observed.Conclusion. The results of the study confirm that the use of the drug according to the proposed method is a safe and effective way of treating pain syndrome during radiotherapy in patients with metastatic bone damage.
- 1 January 2022
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 11 (4)
Clinical features of lung cancer skeletal metastases and the efficiency of palliative radiotherapy
- 1 January 2022
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 11 (4)
Clinical features of lung cancer skeletal metastases and the efficiency of palliative radiotherapy
- 1 January 2022
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 11 (4) , 62
Efficiency of hypofractionated radiotherapy for bone metastases in a female patient with advanced skin melanoma
Метастатическое поражение костей при меланоме кожи является частой локализацией диссеминации опухолевого процесса и встречается в 45% случаев, приводит к существенному снижению качества жизни за счет выраженного болевого синдрома. Вследствие исторического восприятия меланомы кожи как высокорадиорезистентной опухоли некоторые онкологи даже сейчас выступают против проведения лучевой терапии при этой патологии. Однако репутация меланомы как опухоли, нечувствительной к радиотерапии, не подтвердилась при гипофракционировании дозы лучевой терапии.
- 1 January 2022
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 11 (4) , 62
Efficiency of hypofractionated radiotherapy for bone metastases in a female patient with advanced skin melanoma
Метастатическое поражение костей при меланоме кожи является частой локализацией диссеминации опухолевого процесса и встречается в 45% случаев, приводит к существенному снижению качества жизни за счет выраженного болевого синдрома. Вследствие исторического восприятия меланомы кожи как высокорадиорезистентной опухоли некоторые онкологи даже сейчас выступают против проведения лучевой терапии при этой патологии. Однако репутация меланомы как опухоли, нечувствительной к радиотерапии, не подтвердилась при гипофракционировании дозы лучевой терапии.
- Open Access
- 23 June 2021
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 8 (2) , 90-108
New WHO guidelines for cancer pain in adults and adolescents
In this article we performed publication analysis devoted to pain medicine in oncology during anticancer therapy and in palliative setting. Until recently, the main WHO guidelines for pain management in oncology were the recommendations of 1996, which included only pain relievers, as well as adjuvant and symptomatic drugs, which were applied according to the WHO analgesic ladder. These recommendations were based on the collective expert opinion of leading clinicians and scientists. The new WHO clinical guidelines were published in 2019. They are based on the principles of evidence-based medicine, including modern concepts of the etiology and pathogenesis of tumor pain syndrome. This recommendations contain sections on the analgesic efficacy of radiation therapy and antitumor drug therapy. The new WHO recommendations have not yet been published in Russian and are not sufficiently available for a wide range of oncologists and palliative specialists in our country. The purpose of this publication is to present within one volume a concise but complete and comprehensible discussion of the latest trends in pain therapy in oncology, published by WHO experts.
- 23 June 2021
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 8 (2) , 90-108
Open AccessNew WHO guidelines for cancer pain in adults and adolescents
In this article we performed publication analysis devoted to pain medicine in oncology during anticancer therapy and in palliative setting. Until recently, the main WHO guidelines for pain management in oncology were the recommendations of 1996, which included only pain relievers, as well as adjuvant and symptomatic drugs, which were applied according to the WHO analgesic ladder. These recommendations were based on the collective expert opinion of leading clinicians and scientists. The new WHO clinical guidelines were published in 2019. They are based on the principles of evidence-based medicine, including modern concepts of the etiology and pathogenesis of tumor pain syndrome. This recommendations contain sections on the analgesic efficacy of radiation therapy and antitumor drug therapy. The new WHO recommendations have not yet been published in Russian and are not sufficiently available for a wide range of oncologists and palliative specialists in our country. The purpose of this publication is to present within one volume a concise but complete and comprehensible discussion of the latest trends in pain therapy in oncology, published by WHO experts.
- 22 February 2021
- Published by Science and Education A New Dimension in Science and Education a New Dimension
- Vol. IX(250) (31) , 23-25
Clinical features of nasal bleeding in the background of antithrombotic therapy
- 22 February 2021
- Published by Science and Education A New Dimension in Science and Education a New Dimension
- Vol. IX(250) (31) , 23-25
Clinical features of nasal bleeding in the background of antithrombotic therapy
- 1 January 2021
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 10 (5)
Skeletal metastases of colorectal cancer: clinical features and the efficiency of radiotherapy
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение клинических особенностей и эффективности лучевой терапии метастазов колоректального рака в скелете. МАТЕРИАЛ И МЕТОДЫ Исследование, состоявшее из 3 этапов, включало 810 курсов лучевой терапии у больных с костными метастазами различных первичных локализаций. В 27 случаях больные получали лечение по поводу симптомных и/или осложненных метастазов колоректального рака в скелете. Оценку эффективности лучевой терапии выполняли по следующим критериям: вероятность достижения полного и общего обезболивающего эффекта, относительная величина редукции боли и частота рецидивов болевого синдрома. Облучение проводили по методике широкопольного облучения, используя различные варианты дистанционной фотонной лучевой терапии. В соответствии с протоколом исследования разовая очаговая доза составляла 6,5 Гр, число фракций — от 2 до 4, суммарная очаговая доза — 13—26 Гр. РЕЗУЛЬТАТЫ Средняя длительность наблюдения составила 5 мес (от 1 до 19). В 55,6% случаев метастазы локализовались в позвоночнике, в 25,9% — в костях таза. Частота изолированного поражения крестца при колоректальном раке была достоверно выше по сравнению с опухолями молочной железы (p=0,007). Случаи метастазирования в длинные трубчатые кости отсутствовали. Исходная интенсивность болевого синдрома, частота патологических переломов при метастазах колоректального рака достоверно не отличались от средних значений для всех первичных локализаций. Протяженность поражения была достоверно выше по сравнению с костными метастазами рака легкого (p=0,001) и почки (p=0,004). Общая эффективность лучевой терапии составила 96,3%. Частота рецидивов болевого синдрома — 3,7%. Вероятность достижения полного обезболивания в случае костных метастазов колоректального рака оказалась одной из самых низких среди всех первичных локализаций и составила 33,3% против 62,9% (p=0,008) при метастазах рака молочной железы. Относительная редукция боли (процент снижения болевого синдрома относительно исходного уровня) была также достоверно ниже по сравнению с метастазами рака молочной железы и простаты — 67,3% против 82,3% (p=0,0017) и 81,3% (p=0,012) соответственно. ЗАКЛЮЧЕНИЕ Костные метастазы колоректального рака относятся к числу сравнительно радиорезистентных поражений. В то же время высокая общая эффективность облучения в дозе 26 Гр за 4 фракции по 6,5 Гр, составившая более 95%, с вероятностью рецидива болевого синдрома менее 5% случаев за весь период наблюдения позволяет рекомендовать данный вариант лучевой терапии для использования в широкой клинической практике.
- 1 January 2021
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 10 (5)
Skeletal metastases of colorectal cancer: clinical features and the efficiency of radiotherapy
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение клинических особенностей и эффективности лучевой терапии метастазов колоректального рака в скелете. МАТЕРИАЛ И МЕТОДЫ Исследование, состоявшее из 3 этапов, включало 810 курсов лучевой терапии у больных с костными метастазами различных первичных локализаций. В 27 случаях больные получали лечение по поводу симптомных и/или осложненных метастазов колоректального рака в скелете. Оценку эффективности лучевой терапии выполняли по следующим критериям: вероятность достижения полного и общего обезболивающего эффекта, относительная величина редукции боли и частота рецидивов болевого синдрома. Облучение проводили по методике широкопольного облучения, используя различные варианты дистанционной фотонной лучевой терапии. В соответствии с протоколом исследования разовая очаговая доза составляла 6,5 Гр, число фракций — от 2 до 4, суммарная очаговая доза — 13—26 Гр. РЕЗУЛЬТАТЫ Средняя длительность наблюдения составила 5 мес (от 1 до 19). В 55,6% случаев метастазы локализовались в позвоночнике, в 25,9% — в костях таза. Частота изолированного поражения крестца при колоректальном раке была достоверно выше по сравнению с опухолями молочной железы (p=0,007). Случаи метастазирования в длинные трубчатые кости отсутствовали. Исходная интенсивность болевого синдрома, частота патологических переломов при метастазах колоректального рака достоверно не отличались от средних значений для всех первичных локализаций. Протяженность поражения была достоверно выше по сравнению с костными метастазами рака легкого (p=0,001) и почки (p=0,004). Общая эффективность лучевой терапии составила 96,3%. Частота рецидивов болевого синдрома — 3,7%. Вероятность достижения полного обезболивания в случае костных метастазов колоректального рака оказалась одной из самых низких среди всех первичных локализаций и составила 33,3% против 62,9% (p=0,008) при метастазах рака молочной железы. Относительная редукция боли (процент снижения болевого синдрома относительно исходного уровня) была также достоверно ниже по сравнению с метастазами рака молочной железы и простаты — 67,3% против 82,3% (p=0,0017) и 81,3% (p=0,012) соответственно. ЗАКЛЮЧЕНИЕ Костные метастазы колоректального рака относятся к числу сравнительно радиорезистентных поражений. В то же время высокая общая эффективность облучения в дозе 26 Гр за 4 фракции по 6,5 Гр, составившая более 95%, с вероятностью рецидива болевого синдрома менее 5% случаев за весь период наблюдения позволяет рекомендовать данный вариант лучевой терапии для использования в широкой клинической практике.
- Open Access
- 30 July 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 265-270-270
The possibilities of using xenon therapy in patients with severe cancer pain
In accordance with the clinical recommendations of the World Health Organization and the Ministry of Health of the Russian Federation, the main analgesics for the treatment of chronic cancer pain are non-opioid and opioid analgesics, given stepwise in combination with co-analgesics and adjuvant drugs. As a rule, this stepwise scheme of painkilling is effective in most cases. However, 20-30% of patients cannot achieve an acceptable level of pain relief despite the use of these analgesics in combination. Is there another way to help such patients? Interventional methods of analgesia are an option, yet not all patients agree to invasive methods due to the possible side effects and unavailability of these methods. In these cases other mechanisms of analgesia are required, such as NMDA receptor antagonists, which reduce opioid tolerance and hyperalgesia. Still not all the drugs of this group can be applied in our practice. Analgesic properties of nitrous oxide can only be found in high anesthetic doses. Another option is metadon, but it is forbidden and cannot be used in our country. Still one more option is ketamine, which has severe side effects. In our clinical practice we decided to use xenon, which has NMDA inhibition effects. Its analgesic effect and safety have been confirmed in numerous studies. This publication aims to demonstrate a successful clinical case when we used xenon and oxygen inhalations course for the treatment of a severe cancer pain with a patient who had been taking morphine by mouth.
- 30 July 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 265-270-270
Open AccessThe possibilities of using xenon therapy in patients with severe cancer pain
In accordance with the clinical recommendations of the World Health Organization and the Ministry of Health of the Russian Federation, the main analgesics for the treatment of chronic cancer pain are non-opioid and opioid analgesics, given stepwise in combination with co-analgesics and adjuvant drugs. As a rule, this stepwise scheme of painkilling is effective in most cases. However, 20-30% of patients cannot achieve an acceptable level of pain relief despite the use of these analgesics in combination. Is there another way to help such patients? Interventional methods of analgesia are an option, yet not all patients agree to invasive methods due to the possible side effects and unavailability of these methods. In these cases other mechanisms of analgesia are required, such as NMDA receptor antagonists, which reduce opioid tolerance and hyperalgesia. Still not all the drugs of this group can be applied in our practice. Analgesic properties of nitrous oxide can only be found in high anesthetic doses. Another option is metadon, but it is forbidden and cannot be used in our country. Still one more option is ketamine, which has severe side effects. In our clinical practice we decided to use xenon, which has NMDA inhibition effects. Its analgesic effect and safety have been confirmed in numerous studies. This publication aims to demonstrate a successful clinical case when we used xenon and oxygen inhalations course for the treatment of a severe cancer pain with a patient who had been taking morphine by mouth.
- Open Access
- 9 December 2019
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 19,p. 165-168
Treatment of variable pain syndrome in radiation therapy of bone metastases of breast cancer
Лечение вариативного болевого синдрома при лучевой терапии костных метастазов рака молочной железы
- 9 December 2019
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 19,p. 165-168
Open AccessTreatment of variable pain syndrome in radiation therapy of bone metastases of breast cancer
Лечение вариативного болевого синдрома при лучевой терапии костных метастазов рака молочной железы